Increased vs. Standard Dose of Iron in Ready-to-Use Therapeutic Foods for the Treatment of Severe Acute Malnutrition in a Community Setting: A Systematic Review and Meta-Analysis

The optimal dose of iron in ready-to-use therapeutic foods (RUTF) used to treat uncomplicated severe acute malnutrition (SAM) in community settings is not well established. The objective of this systematic review was to assess if an increased iron dose in RUTF, compared with the standard iron dose in the World Health Organization (WHO)-recommended peanut-based RUTF, improved outcomes in children aged six months or older. We searched multiple electronic databases and only included randomized controlled trials. We pooled the data in a meta-analysis to obtain relative risk (RR) and reported it with a 95% confidence interval (CI). Three studies, one each from Zambia, the Democratic Republic of Congo, and Malawi, were included. In all studies, the RUTF used in the intervention group was milk-free soya–maize–sorghum-based RUTF. The pooled results showed that, compared to the control group, a high iron content in RUTF may lead to increase in hemoglobin concentration (mean difference 0.33 g/dL, 95% CI: 0.02, 0.64, two studies, certainty of evidence: low) and a decrease in any anemia (RR 0.66, 95% CI: 0.48, 0.91, two studies, certainty of evidence: low), but also decrease recovery rates (RR 0.91, 95% CI: 0.84, 0.99, three studies, certainty of evidence: low) and increase mortality (RR 1.30, 95% CI: 0.87, 1.95, three studies, certainty of evidence: moderate). However, the CIs were imprecise for the latter outcome. Future studies with large sample sizes are needed to confirm the beneficial versus harmful effects of high iron content in RUTF in treating uncomplicated SAM in children aged 6-59 months in community settings.


Introduction
The World Health Organization (WHO) reports that about 45 million children under the age of five worldwide suffered from wasting (low weight for height) in the year follow-up: 1 month vs. 3 months vs. 6 months follow-up, and longest follow-up [18]. None of these subgroup analyses were performed because the number of included studies was small. We also planned sensitivity analyses based on studies with a high risk of bias and the type of model used: random vs. fixed-effect model. Only the latter was performed due to the limited number of studies.

Patient and Public Involvement
No patient or public involvement was considered in the preparation of the protocol or the review.

Literature Search
The literature search identified 393 titles after the exclusion of duplicates. Figure 1 shows the results of the literature search. After screening the full texts of 19 studies for eligibility, we ultimately included three studies [4,12,25]. reported in five publications [4,12,[25][26][27]. (complete list in Annex S1 in Supplementary document). We excluded 14 studies, and the reasons for exclusion can be found in Annex S2.

Characteristics of Included Studies
Tables 1 and 2 display the characteristics of the included studies for participants and interventions, respectively.  Ad libitum -10.5 mg/100 g RUTF Recovery rates, mortality, anemia a dose: mg/100 g of RUTF. Abbreviations: FSMS-RUTF: dairy-free soya-maize-sorghum ready-to-use therapeutic food, RUTF: ready-to-use therapeutic food. SMS-RUTF: soya-maizesorghum-based ready-to-use therapeutic food. SAM: severe acute malnutrition All three included studies were randomized controlled trials conducted in Africa. The studies' median sample size was 886 [12]. participants, ranging from 392 [4]. participants to 1927 [25]. participants. All studies investigated an intervention using RUTF with an iron content higher than that of the current WHO standard RUTF for treatment of SAM in children aged 6-59 months in community settings. In all studies, the RUTF with a high iron content was soya-maize-sorghum (SMS)-based. The macronutrient and micronutrient compositions of the intervention-and comparison-group RUTF for each study are described in Table 3. Table 3. Macronutrient and micronutrient composition of RUTF in the included studies.

Studies with Multiple Intervention Arms and Missing Data
One study had two treatment arms: soybean, maize and sorghum (SMS), with milk (MSMS-RUTF) and without milk (FSMS-RUTF) [4]. We used the data from the (FSMS-RUTF) group only, as the other two included groups also used an RUTF that was non-dairy SMS-based. One of the included studies was a cluster randomized trial [25]. The sample size of this cluster randomized trial was adjusted for the cluster design [25], so we did not make any further adjustments. Even though all the studies contributed data for the meta-analysis, they did not all contribute to every outcome in the review.

Effects of Interventions
In the section below, we report the meta-analysis and GRADE analysis results for each primary outcome and key secondary outcomes at the longest follow-up. Table 4 shows GRADE evidence profiles for the same outcomes. Abbreviations: CI: confidence interval; MD: mean difference; RCT: randomized controlled trial; RR: risk ratio, SAM: severe acute malnutrition, SMS: soya-maize-sorghum, WHO: World Health Organization. Interpretation of certainty ratings: very low (we have very little confidence in the effect estimate), low (we have limited confidence in the effect estimate), moderate (we have moderate confidence in the effect estimate; the true effect is likely close to the estimate of the effect), or high (we have high confidence that the true effect lies close to that of the estimate of the effect). a Both of the included studies in this analysis were at a high risk of bias for this outcome. The data from both studies were available only for a subset of the patients. b Even though the unexplained statistical heterogeneity was 52%, based on I 2 statistics, the direction of effect was in the same direction. We did not downgrade for inconsistency. c The overall effect seems to be small. Even though the confidence interval of the summary estimate did not include a null effect, the lower limit of the confidence limit was very near to the null effect. The results of the blood hemoglobin from both studies were not adjusted for ethnicity or altitude. d Both the included studies were at high risk of bias due to lack of data for the full set of study participants. e Even though the confidence interval around the summary estimate did not include 1, the upper limit approached a null effect. In addition, the values of hemoglobin were not adjusted for altitude and ethnicity. f The only included study was at high risk of bias due to data available only for a subset of patients included in the study. g The analysis included only one study with a total of 22 events in both groups. The confidence interval around the summary estimate was wide. In addition, the upper limit of the confidence interval of the summary estimate reached almost a null effect. h The confidence interval of the summary estimate was wide and included a null effect. I Even though the direction of effect was in favor of a high iron dose in RUTF, the magnitude of effect differed among the included studies. The unexplained statistical heterogeneity was 76%, based on I 2 statistics. j The upper limit of the confidence interval around the summary estimate almost reached a null effect. k The confidence interval around the summary estimate included a null effect with the possibility of a beneficial effect or an increased risk of mortality. l The magnitude of the effect varied among the studies. The I 2 was 60%. m The confidence interval around the summary estimate included a null effect with the possibility of a beneficial effect or an increased risk of withdrawal from study.

Blood Hemoglobin Concentration (g/dL) at the Longest Follow-Up
Two randomized controlled trials [4,12]. reported data on blood hemoglobin concentration, and both had data available only for a subset of the population. Data for hemoglobin at the end of the individual studies were pooled from these two studies, which included 451 participants, with 219 participants in the high-iron RUTF group and 232 in the WHO standard-iron RUTF group. The results showed low certainty evidence that there may be a small increase in hemoglobin concentration among children aged 6-59 months receiving RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (mean difference 0.33 g/dL, 95% CI: 0.02, 0.64, p = 0.04, I 2 = 52%, Figure 2). We downgraded the GRADE certainty for risk of bias (because both of the included studies [4,12] reported data for only a subset of the study population, Annex S3, Supplementary document) and imprecision of the summary estimate (the overall effect seems to be small; the lower limit of the confidence interval was very close to the null effect, and the results of the blood hemoglobin were not adjusted for ethnicity and altitude) ( Table 4).
Nutrients 2022, 14, x FOR PEER REVIEW 9 of 23 hemoglobin at the end of the individual studies were pooled from these two studies, which included 451 participants, with 219 participants in the high-iron RUTF group and 232 in the WHO standard-iron RUTF group. The results showed low certainty evidence that there may be a small increase in hemoglobin concentration among children aged 6-59 months receiving RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (mean difference 0.33 g/dL, 95% CI: 0.02, 0.64, p = 0.04, I 2 = 52%, Figure 2). We downgraded the GRADE certainty for risk of bias (because both of the included studies [4,12] reported data for only a subset of the study population, Annex S3, Supplementary document) and imprecision of the summary estimate (the overall effect seems to be small; the lower limit of the confidence interval was very close to the null effect, and the results of the blood hemoglobin were not adjusted for ethnicity and altitude) ( Table 4).

Figure 2.
Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on blood hemoglobin (g/dL). The forest plot shows pooled data from two studies for change in hemoglobin at the end of the study. Both the studies had data available only for a subset of population. The published data from Akomo 2019 [4]. was adjusted for altitude and ethnicity; however, we had access to unadjusted data, and we pooled the same to be consistent with data from Bahwere's 2016 [12]. study that were not adjusted. The data from Bahwere 2016 was provided by authors and was not available from the published report. Akomo 2019 has two study groups. We included data from milk-free soybean, maize, and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-readyto-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Subgroup and Sensitivity Analyses
The a priori subgroup analyses planned for age group (<24 months vs. 24-59 months vs. >59 months), country, type of RUTF, type of participants (studies that included children with HIV vs. studies that did not include children with HIV), hospitalization, iron compound, anemia status, and time of follow-up were not conducted because there were not enough data in the included studies. Sensitivity analysis based on the type of model used showed similar results for the fixed vs. random effects model of the meta-analysis (MD: 0.31, 95% CI: 0.10, 0.52, fixed models).

Any Anemia at the Longest Follow-Up
Two randomized controlled trials [4,12]. reported data on anemia, and both had data available only for a subset of the population. Anemia was defined in both studies [4,12]. as blood hemoglobin < 11 mg/dL. The data on hemoglobin from one study [12]. were not available from the published report but were provided upon request by the authors; these data were not adjusted for altitude and ethnicity. The published data from the second study [4]. were adjusted for altitude and ethnicity; however, we had access to unadjusted data. We pooled the same to be consistent with the data from the first study. Data for any anemia at the end of the study were pooled from these two studies, which included 451 participants, with 219 participants in the high-iron RUTF group and 232 in the WHO standard-iron RUTF group. The results showed a low certainty of evidence that the risk of anemia may be lower in children aged 6-59 months receiving RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (RR 0.66, 95% CI: 0.48, 0.91, p = 0.01, I 2 = 32%, Figure 3). We downgraded the GRADE certainty for risk of bias (for which there was 'serious concern' for a high risk of bias because both of the two included studies [4,12]. reported data for only a subset of the study population) Figure 2. Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on blood hemoglobin (g/dL). The forest plot shows pooled data from two studies for change in hemoglobin at the end of the study. Both the studies had data available only for a subset of population. The published data from Akomo 2019 [4]. was adjusted for altitude and ethnicity; however, we had access to unadjusted data, and we pooled the same to be consistent with data from Bahwere's 2016 [12]. study that were not adjusted. The data from Bahwere 2016 was provided by authors and was not available from the published report. Akomo 2019 has two study groups. We included data from milk-free soybean, maize, and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Subgroup and Sensitivity Analyses
The a priori subgroup analyses planned for age group (<24 months vs. 24-59 months vs. >59 months), country, type of RUTF, type of participants (studies that included children with HIV vs. studies that did not include children with HIV), hospitalization, iron compound, anemia status, and time of follow-up were not conducted because there were not enough data in the included studies. Sensitivity analysis based on the type of model used showed similar results for the fixed vs. random effects model of the meta-analysis (MD: 0.31, 95% CI: 0.10, 0.52, fixed models).

Any Anemia at the Longest Follow-Up
Two randomized controlled trials [4,12]. reported data on anemia, and both had data available only for a subset of the population. Anemia was defined in both studies [4,12]. as blood hemoglobin < 11 mg/dL. The data on hemoglobin from one study [12]. were not available from the published report but were provided upon request by the authors; these data were not adjusted for altitude and ethnicity. The published data from the second study [4]. were adjusted for altitude and ethnicity; however, we had access to unadjusted data. We pooled the same to be consistent with the data from the first study. Data for any anemia at the end of the study were pooled from these two studies, which included 451 participants, with 219 participants in the high-iron RUTF group and 232 in the WHO standard-iron RUTF group. The results showed a low certainty of evidence that the risk of anemia may be lower in children aged 6-59 months receiving RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (RR 0.66, 95% CI: 0.48, 0.91, p = 0.01, I 2 = 32%, Figure 3). We downgraded the GRADE certainty for risk of bias (for which there was 'serious concern' for a high risk of bias because both of the two included studies [4,12]. reported data for only a subset of the study population) and imprecision (for which there was 'serious concern' because the confidence interval around the summary estimate almost approached the null effect and the values of hemoglobin were not adjusted for altitude and ethnicity) ( Table 4).
Nutrients 2022, 14, x FOR PEER REVIEW 10 of 23 and imprecision (for which there was 'serious concern' because the confidence interval around the summary estimate almost approached the null effect and the values of hemoglobin were not adjusted for altitude and ethnicity) ( Table 4).

Figure 3.
Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on any anemia. The forest plot shows pooled data from two studies. The data on hemoglobin from Bahwere 2016 [12]. was not adjusted for altitude and ethnicity. The published data from Akomo 2019 [4]. was adjusted for altitude and ethnicity; however, we had access to unadjusted data and we pooled the same to be consistent with data from Bahwere's 2016 study. The data from Bahwere 2016 was provided by authors and was not available from the published report. Akomo 2019 has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). The overall results indicate that risk of anemia might be lower in group that received RUTF with high iron content. Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Subgroup and Sensitivity Analyses
None of the a priori subgroup analyses were performed for this outcome due to the lack of available data in the included studies. A sensitivity analysis based on the type of model showed similar results (RR 0.65, 95% CI: 0.50, 0.85. fixed effects).

Iron Deficiency Anemia at the Longest Follow-Up
One randomized controlled trial [4]. reported data on iron deficiency anemia; data were only available for a subset of the population. The hemoglobin results were adjusted for altitude and ethnicity. Data for iron deficiency anemia at the end of the study included 146 participants, with 63 participants in the high-iron RUTF group and 83 in the WHO standard-iron RUTF group. The results showed a low certainty of evidence that the risk of iron deficiency anemia may be lower in children aged 6-59 months receiving RUTF with a high iron content compared to those receiving RUTF with the WHO standard iron dose (RR 0.39, 95% CI: 0.15, 0.99, p = 0.05, Figure 4). We downgraded the GRADE certainty for risk of bias (for which there was 'serious concern' for a high risk of bias because the study [4]. reported data for only a subset of the study population) and imprecision (for which there was 'serious concern' because the analysis included only one study with a total of 22 events in both groups, the confidence interval around the summary estimate was imprecise, and the upper limit of the confidence interval almost reached a null effect) ( Table 4). . Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on iron deficiency anemia. The forest plot shows data from a single study and this study had data available only for a subset of population. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum. Figure 3. Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on any anemia. The forest plot shows pooled data from two studies. The data on hemoglobin from Bahwere 2016 [12]. was not adjusted for altitude and ethnicity. The published data from Akomo 2019 [4]. was adjusted for altitude and ethnicity; however, we had access to unadjusted data and we pooled the same to be consistent with data from Bahwere's 2016 study. The data from Bahwere 2016 was provided by authors and was not available from the published report. Akomo 2019 has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). The overall results indicate that risk of anemia might be lower in group that received RUTF with high iron content. Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Subgroup and Sensitivity Analyses
None of the a priori subgroup analyses were performed for this outcome due to the lack of available data in the included studies. A sensitivity analysis based on the type of model showed similar results (RR 0.65, 95% CI: 0.50, 0.85. fixed effects).

Iron Deficiency Anemia at the Longest Follow-Up
One randomized controlled trial [4]. reported data on iron deficiency anemia; data were only available for a subset of the population. The hemoglobin results were adjusted for altitude and ethnicity. Data for iron deficiency anemia at the end of the study included 146 participants, with 63 participants in the high-iron RUTF group and 83 in the WHO standard-iron RUTF group. The results showed a low certainty of evidence that the risk of iron deficiency anemia may be lower in children aged 6-59 months receiving RUTF with a high iron content compared to those receiving RUTF with the WHO standard iron dose (RR 0.39, 95% CI: 0.15, 0.99, p = 0.05, Figure 4). We downgraded the GRADE certainty for risk of bias (for which there was 'serious concern' for a high risk of bias because the study [4]. reported data for only a subset of the study population) and imprecision (for which there was 'serious concern' because the analysis included only one study with a total of 22 events in both groups, the confidence interval around the summary estimate was imprecise, and the upper limit of the confidence interval almost reached a null effect) ( Table 4). and imprecision (for which there was 'serious concern' because the confidence interval around the summary estimate almost approached the null effect and the values of hemoglobin were not adjusted for altitude and ethnicity) ( Table 4).

Figure 3.
Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on any anemia. The forest plot shows pooled data from two studies. The data on hemoglobin from Bahwere 2016 [12]. was not adjusted for altitude and ethnicity. The published data from Akomo 2019 [4]. was adjusted for altitude and ethnicity; however, we had access to unadjusted data and we pooled the same to be consistent with data from Bahwere's 2016 study. The data from Bahwere 2016 was provided by authors and was not available from the published report. Akomo 2019 has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). The overall results indicate that risk of anemia might be lower in group that received RUTF with high iron content. Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Subgroup and Sensitivity Analyses
None of the a priori subgroup analyses were performed for this outcome due to the lack of available data in the included studies. A sensitivity analysis based on the type of model showed similar results (RR 0.65, 95% CI: 0.50, 0.85. fixed effects).

Iron Deficiency Anemia at the Longest Follow-Up
One randomized controlled trial [4]. reported data on iron deficiency anemia; data were only available for a subset of the population. The hemoglobin results were adjusted for altitude and ethnicity. Data for iron deficiency anemia at the end of the study included 146 participants, with 63 participants in the high-iron RUTF group and 83 in the WHO standard-iron RUTF group. The results showed a low certainty of evidence that the risk of iron deficiency anemia may be lower in children aged 6-59 months receiving RUTF with a high iron content compared to those receiving RUTF with the WHO standard iron dose (RR 0.39, 95% CI: 0.15, 0.99, p = 0.05, Figure 4). We downgraded the GRADE certainty for risk of bias (for which there was 'serious concern' for a high risk of bias because the study [4]. reported data for only a subset of the study population) and imprecision (for which there was 'serious concern' because the analysis included only one study with a total of 22 events in both groups, the confidence interval around the summary estimate was imprecise, and the upper limit of the confidence interval almost reached a null effect) ( Table 4).

Figure 4.
Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on iron deficiency anemia. The forest plot shows data from a single study and this study had data available only for a subset of population. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum. Figure 4. Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on iron deficiency anemia. The forest plot shows data from a single study and this study had data available only for a subset of population. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Subgroup and Sensitivity Analyses
None of the a priori subgroup analyses or sensitivity analyses were performed for this outcome.
3.6.3. Severe Anemia (Hemoglobin < 9 mg/dL) at the Longest Follow-Up Two randomized controlled trials [4,12] reported data on severe anemia, and both had data available only for a subset of the population. Data for severe anemia at the end of the study were pooled from these two studies, which included 451 participants, with 219 participants in the high-iron RUTF group and 232 in the WHO standard-iron RUTF group. The results showed a low certainty of evidence that risk of severe anemia might be lower in children aged 6-59 months receiving RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (RR 0.88, 95% CI: 0.30, 2.56, p = 0.81, I 2 = 0%, Figure 5). We downgraded the GRADE certainty for risk of bias (for which there was 'serious concern' for high risk of bias because both of the two included studies [4,12]. reported data for only a subset of the study population) and imprecision (the number of events were small, and the confidence interval of the summary estimate included a null effect). None of the a priori subgroup analyses or sensitivity analyses were performed for this outcome.
3.6.3. Severe Anemia (Hemoglobin < 9 mg/dL) at the Longest Follow-Up Two randomized controlled trials 4,12 reported data on severe anemia, and both had data available only for a subset of the population. Data for severe anemia at the end of the study were pooled from these two studies, which included 451 participants, with 219 participants in the high-iron RUTF group and 232 in the WHO standard-iron RUTF group. The results showed a low certainty of evidence that risk of severe anemia might be lower in children aged 6-59 months receiving RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (RR 0.88, 95% CI: 0.30, 2.56, p = 0.81, I 2 = 0%, Figure 5). We downgraded the GRADE certainty for risk of bias (for which there was 'serious concern' for high risk of bias because both of the two included studies [4,12]. reported data for only a subset of the study population) and imprecision (the number of events were small, and the confidence interval of the summary estimate included a null effect). Figure 5. Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on severe anemia (Blood Hemoglobin < 9 mg/dL). The forest plot shows pooled data from two studies. Data were available only for a subset of population from both the studies. The blood hemoglobin results were not adjusted for altitude and ethnicity. The data was provided by authors of the primary studies and was not available from the published papers. Akomo 2019 has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and standard formulation prepared from peanut and milk (PM-RUTF). Abbreviations: RUTF-ready-touse therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Subgroup and Sensitivity Analyses
None of the a priori subgroup analyses were performed for this outcome and a sensitivity analysis-based model showed similar results (RR 0.88, 95% CI 0.30, 2.56. fixed effects).

Recovery from SAM at the Longest Follow-Up
Three randomized controlled trials [4,12,25]. reported data on recovery from SAM. Raw values were used to calculate the summary estimate from individual studies, and an intention-to-treat analysis was preferred, where available. Data for recovery from SAM at the end of the study were pooled from these three studies, which included 3681 participants, with 1696 participants in the high-iron RUTF group and 1985 in the WHO standardiron RUTF group. The results showed a low certainty of evidence that the rate of recovery may be lower for children aged 6-59 months receiving SMS-based RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (RR 0.91, 95% CI: 0.84, 0.99, p = 0.04, I 2 = 76%, Figure 6). We downgraded the GRADE certainty for inconsistency (for which there was 'serious concern' because even though the magnitude of effect differed among the included studies, with an I 2 of 76%) and imprecision (for which there was 'serious concern' because the upper limit of the confidence interval around the summary estimate almost reached a null effect) ( Table 4).

Figure 5.
Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on severe anemia (Blood Hemoglobin < 9 mg/dL). The forest plot shows pooled data from two studies. Data were available only for a subset of population from both the studies. The blood hemoglobin results were not adjusted for altitude and ethnicity. The data was provided by authors of the primary studies and was not available from the published papers. Akomo 2019 has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and standard formulation prepared from peanut and milk (PM-RUTF). Abbreviations: RUTF-readyto-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Subgroup and Sensitivity Analyses
None of the a priori subgroup analyses were performed for this outcome and a sensitivity analysis-based model showed similar results (RR 0.88, 95% CI 0.30, 2.56. fixed effects).

Recovery from SAM at the Longest Follow-Up
Three randomized controlled trials [4,12,25]. reported data on recovery from SAM. Raw values were used to calculate the summary estimate from individual studies, and an intention-to-treat analysis was preferred, where available. Data for recovery from SAM at the end of the study were pooled from these three studies, which included 3681 participants, with 1696 participants in the high-iron RUTF group and 1985 in the WHO standard-iron RUTF group. The results showed a low certainty of evidence that the rate of recovery may be lower for children aged 6-59 months receiving SMS-based RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (RR 0.91, 95% CI: 0.84, 0.99, p = 0.04, I 2 = 76%, Figure 6). We downgraded the GRADE certainty for inconsistency (for which there was 'serious concern' because even though the magnitude of effect differed among the included studies, with an I 2 of 76%) and imprecision (for which there was 'serious concern' because the upper limit of the confidence interval around the summary estimate almost reached a null effect) ( Table 4).
Nutrients 2022, 14, x FOR PEER REVIEW 12 of 23 Figure 6. Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on recovery from severe acute malnutrition. The forest plot shows pooled data from all three included studies from this review. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential decrease in recovery rates for children receiving RUTF with high iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Adverse Events
Three randomized controlled trials [4,12,25]. reported data on adverse effects. The data were reported so that it could not be meta-analyzed, so we present the results in Table 5. None of these studies reported outcomes regarding the impact of high iron content in RUTF on the incidence of diarrhea and malaria; thus, we could not explore these outcomes, as initially intended. There was no significant difference in the rates of any adverse events or serious adverse events between the SMS-based high-iron RUTF group vs. the control group in any of the included studies. One study [25]. reported that a skin rash occurred in 13.3% of children in the group receiving peanut-based RUTF with the WHO standard iron dose, compared to no skin rash occurring among children in the group receiving RUTF with a high iron content; however, it was noted that all of the children reporting a skin rash were from the same health center, and the rash was mild. Table 5. Description of side-effect profiles in the included studies.

p-Value Notes
Irena 2015 [25] Percentage of children who reported at least one episode of diarrhea % (n) 20.0 (9) 15.6 (7) 0.6 All of the children on P-RUTF who reported skin rash were from the same health center, and the rash was not specific to certain body parts; it was itchy and appeared as mild with no pustules or vesicles.

(6) -
Bahwere 2016 [12] Percentage of children with side-effects related to RUTF intake % (n/N) 2.74 (2/73) 2.22 (2/45) 0.862 No serious side-effects were detected, and no reasons for interrupting the study were identified. No difference was noted in rates of diarrhea, fever, or abdominal pain, and data were the same for children <24 months and >24 months.
Akomo 2019 [4] Percentage of children with inflammation-adjusted plasma ferritin at discharge > 100 μg/L, indicative of excess iron reserve % (n/N) 1.6 (1/64) 4.8 (4/84) 0.559 There was no effect of iron content on risk of iron overload or gut inflammation. Complaints of fever, diarrhea, or cough were rare in all study arms in both age groups, with a comparison of median values showing no statistical differences.
Abbreviations: CI: confidence interval; BIS: body iron stores; FSMS-RUTF: milk-free soya-maizesorghum-based ready-to-use therapeutic food; PM-RUTF: peanut-paste-based ready-to-use therapeutic food; RUTF: ready-to-use therapeutic food; SAM: severe acute malnutrition. Figure 6. Effect of SMS-based RUTF with high iron content compared to peanut-based RUTF with WHO standard iron content on recovery from severe acute malnutrition. The forest plot shows pooled data from all three included studies from this review. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential decrease in recovery rates for children receiving RUTF with high iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Adverse Events
Three randomized controlled trials [4,12,25]. reported data on adverse effects. The data were reported so that it could not be meta-analyzed, so we present the results in Table 5. None of these studies reported outcomes regarding the impact of high iron content in RUTF on the incidence of diarrhea and malaria; thus, we could not explore these outcomes, as initially intended. There was no significant difference in the rates of any adverse events or serious adverse events between the SMS-based high-iron RUTF group vs. the control group in any of the included studies. One study [25]. reported that a skin rash occurred in 13.3% of children in the group receiving peanut-based RUTF with the WHO standard iron dose, compared to no skin rash occurring among children in the group receiving RUTF with a high iron content; however, it was noted that all of the children reporting a skin rash were from the same health center, and the rash was mild. Table 5. Description of side-effect profiles in the included studies.

Value in WHO Standard-Iron RUTF Comparison Group p-Value Notes
Irena 2015 [25] Percentage of children who reported at least one episode of diarrhea % (n) 20.0 (9) 15.6 (7) 0.6 All of the children on P-RUTF who reported skin rash were from the same health center, and the rash was not specific to certain body parts; it was itchy and appeared as mild with no pustules or vesicles.
Percentage of children who reported vomiting % (n) 4.4 (2) 6.7 ( No serious side-effects were detected, and no reasons for interrupting the study were identified. No difference was noted in rates of diarrhea, fever, or abdominal pain, and data were the same for children <24 months and >24 months. Akomo 2019 [4] Percentage of children with inflammation-adjusted plasma ferritin at discharge > 100 µg/L, indicative of excess iron reserve % (n/N) 1.6 (1/64) 4.8 (4/84) 0.559 There was no effect of iron content on risk of iron overload or gut inflammation. Complaints of fever, diarrhea, or cough were rare in all study arms in both age groups, with a comparison of median values showing no statistical differences.

Secondary Outcomes
We describe the results of secondary outcomes, for which a GRADE analysis was conducted, in Table 4. The data for the following secondary outcomes were not available: serum zinc, serum copper, relapse, clinical deterioration necessitating referral to inpatient care, height for age, weight for height, microbiome outcomes, and neurodevelopmental outcomes.

All-Cause Mortality at the Longest Follow-Up
Three randomized controlled trials [4,12,25]. reported data on all-cause mortality. Raw values from individual studies were used to calculate the relative risk, and an intentionto-treat analysis was preferred, where available. Data for all-cause mortality at the end of the study were pooled from these three studies, which included 3686 participants, with 1696 participants in the high-iron RUTF group and 1990 in the WHO standard-iron RUTF group. The results showed a moderate certainty of evidence that there may be an increase in all-cause mortality for children aged 6-59 months receiving SMS-based RUTF with a high iron content, compared to those receiving peanut-based RUTF with the WHO standard iron dose (RR 1.30, 95% CI: 0.87, 1.95, p = 0.21, I 2 = 24%, Figure 7); however, a potential beneficial effect cannot be ruled out based on the lower limits of the confidence interval. We downgraded the GRADE certainty for imprecision (for which there was 'serious concern' because the confidence interval around the summary estimate included a null effect with the possibility of a beneficial effect or a decreased risk of mortality) ( Table 4).

Secondary Outcomes
We describe the results of secondary outcomes, for which a GRADE analysis was conducted, in Table 4. The data for the following secondary outcomes were not available: serum zinc, serum copper, relapse, clinical deterioration necessitating referral to inpatient care, height for age, weight for height, microbiome outcomes, and neurodevelopmental outcomes.

All-Cause Mortality at the Longest Follow-Up
Three randomized controlled trials [4,12,25]. reported data on all-cause mortality. Raw values from individual studies were used to calculate the relative risk, and an intention-to-treat analysis was preferred, where available. Data for all-cause mortality at the end of the study were pooled from these three studies, which included 3686 participants, with 1696 participants in the high-iron RUTF group and 1990 in the WHO standard-iron RUTF group. The results showed a moderate certainty of evidence that there may be an increase in all-cause mortality for children aged 6-59 months receiving SMS-based RUTF with a high iron content, compared to those receiving peanut-based RUTF with the WHO standard iron dose (RR 1.30, 95% CI: 0.87, 1.95, p = 0.21, I 2 = 24%, Figure 7); however, a potential beneficial effect cannot be ruled out based on the lower limits of the confidence interval. We downgraded the GRADE certainty for imprecision (for which there was 'serious concern' because the confidence interval around the summary estimate included a null effect with the possibility of a beneficial effect or a decreased risk of mortality) ( Table 4).

Figure 7.
Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on all-cause mortality. The forest plot shows pooled data from all three included studies from this review. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential increase in mortality for children receiving RUTF with high iron content, compared to RUTF with WHO standard iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soyamaize-sorghum.

Withdrawal from Trial
Three randomized controlled trials [4,12,25]. reported data on withdrawal from the study, which included 3681 participants, with 1696 participants in the SMS-based highiron RUTF group and 1985 in the WHO standard-iron peanut-based RUTF group. The results showed a low certainty of evidence that the rates of withdrawal may be higher in children aged 6-59 months receiving SMS-based RUTF with a high iron content, compared to those receiving peanut-based RUTF with the WHO standard iron dose (risk ratio 1.25, 95% CI: 0.98, 1.60, p = 0.08, I 2 = 60%, Figure 8). We downgraded the GRADE certainty for inconsistency (for which there was 'serious concern' because the magnitude of the effect varied among the studies, with an I 2 of 60%) and imprecision (for which there was 'serious concern' because the confidence interval around the summary estimate included a null effect with the possibility of a beneficial effect or a decreased risk of withdrawal from the trial) (Table 4).

Figure 7.
Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on all-cause mortality. The forest plot shows pooled data from all three included studies from this review. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential increase in mortality for children receiving RUTF with high iron content, compared to RUTF with WHO standard iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Withdrawal from Trial
Three randomized controlled trials [4,12,25]. reported data on withdrawal from the study, which included 3681 participants, with 1696 participants in the SMS-based highiron RUTF group and 1985 in the WHO standard-iron peanut-based RUTF group. The results showed a low certainty of evidence that the rates of withdrawal may be higher in children aged 6-59 months receiving SMS-based RUTF with a high iron content, compared to those receiving peanut-based RUTF with the WHO standard iron dose (risk ratio 1.25, 95% CI: 0.98, 1.60, p = 0.08, I 2 = 60%, Figure 8). We downgraded the GRADE certainty for inconsistency (for which there was 'serious concern' because the magnitude of the effect varied among the studies, with an I 2 of 60%) and imprecision (for which there was 'serious concern' because the confidence interval around the summary estimate included a null effect with the possibility of a beneficial effect or a decreased risk of withdrawal from the trial) (Table 4).

Figure 8.
Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on default from trial. The forest plot shows pooled data from all three included studies from this review. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential increase in default rate for children receiving RUTF with high iron content compared to RUTF with WHO standard iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soyamaize-sorghum.

Weight Gain
Two randomized controlled trials [4,12]. reported data on weight gain and the pooled data from these two studies showed that the rate of weight gain was lower among children aged 6-59 months receiving RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (mean difference −0.56 g/dL, 95% CI: −01.61, −0.49, p = 0.003, I 2 = 88%, Figure 9). Figure 9. Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on weight gain. The forest plot shows pooled data from two of the included studies. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential decrease in weight gain with RUTF with high iron content compared to RUTF with WHO standard iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Summary of Main Results
This systematic review and meta-analysis evaluated the effect of a high iron content in SMS-based RUTF versus the iron content in peanut-based RUTF based on current WHO standard guidelines in children aged 6-59 months with uncomplicated SAM. Results from the synthesis suggest low certainty evidence that the use of SMS-based high-iron RUTF, compared to the WHO standard iron content peanut-based RUTF, may lead to an increased blood hemoglobin concentration and decreased risk of any anemia, iron deficiency anemia, and severe anemia. However, low certainty evidence showed that recovery rates may be lower in the high-iron SMS-based RUTF group compared to standardiron peanut-based RUTF in children aged 6-59 months with SAM. A moderate level of certainty of evidence showed that the mortality risk may be higher in the high-iron group, although the confidence interval also included a potentially beneficial effect. The available data on rates of side-effects showed similar rates in the intervention group compared to the control. Figure 8. Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on default from trial. The forest plot shows pooled data from all three included studies from this review. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential increase in default rate for children receiving RUTF with high iron content compared to RUTF with WHO standard iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Weight Gain
Two randomized controlled trials [4,12]. reported data on weight gain and the pooled data from these two studies showed that the rate of weight gain was lower among children aged 6-59 months receiving RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (mean difference −0.56 g/dL, 95% CI: −01.61, −0.49, p = 0.003, I 2 = 88%, Figure 9).
Nutrients 2022, 14, x FOR PEER REVIEW 14 of 23 Figure 8. Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on default from trial. The forest plot shows pooled data from all three included studies from this review. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential increase in default rate for children receiving RUTF with high iron content compared to RUTF with WHO standard iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soyamaize-sorghum.

Weight Gain
Two randomized controlled trials [4,12]. reported data on weight gain and the pooled data from these two studies showed that the rate of weight gain was lower among children aged 6-59 months receiving RUTF with a high iron content, compared to those receiving RUTF with the WHO standard iron dose (mean difference −0.56 g/dL, 95% CI: −01.61, −0.49, p = 0.003, I 2 = 88%, Figure 9). Figure 9. Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on weight gain. The forest plot shows pooled data from two of the included studies. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential decrease in weight gain with RUTF with high iron content compared to RUTF with WHO standard iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Summary of Main Results
This systematic review and meta-analysis evaluated the effect of a high iron content in SMS-based RUTF versus the iron content in peanut-based RUTF based on current WHO standard guidelines in children aged 6-59 months with uncomplicated SAM. Results from the synthesis suggest low certainty evidence that the use of SMS-based high-iron RUTF, compared to the WHO standard iron content peanut-based RUTF, may lead to an increased blood hemoglobin concentration and decreased risk of any anemia, iron deficiency anemia, and severe anemia. However, low certainty evidence showed that recovery rates may be lower in the high-iron SMS-based RUTF group compared to standardiron peanut-based RUTF in children aged 6-59 months with SAM. A moderate level of certainty of evidence showed that the mortality risk may be higher in the high-iron group, although the confidence interval also included a potentially beneficial effect. The available data on rates of side-effects showed similar rates in the intervention group compared to the control. Figure 9. Effect of SMS-based RUTF with high iron content compared to that of peanut-based RUTF with WHO standard iron content on weight gain. The forest plot shows pooled data from two of the included studies. Raw values were used, and an intention-to-treat analysis was preferred, where available. The pooled results show a potential decrease in weight gain with RUTF with high iron content compared to RUTF with WHO standard iron content. Akomo 2019 [4]. has two study groups. We included data from milk-free soybean, maize and sorghum (FSMS) and a standard formulation prepared from peanuts and milk (PM-RUTF). Abbreviations: RUTF-ready-to-use therapeutic food; WHO-World Health Organization; SMS-soya-maize-sorghum.

Summary of Main Results
This systematic review and meta-analysis evaluated the effect of a high iron content in SMS-based RUTF versus the iron content in peanut-based RUTF based on current WHO standard guidelines in children aged 6-59 months with uncomplicated SAM. Results from the synthesis suggest low certainty evidence that the use of SMS-based high-iron RUTF, compared to the WHO standard iron content peanut-based RUTF, may lead to an increased blood hemoglobin concentration and decreased risk of any anemia, iron deficiency anemia, and severe anemia. However, low certainty evidence showed that recovery rates may be lower in the high-iron SMS-based RUTF group compared to standard-iron peanutbased RUTF in children aged 6-59 months with SAM. A moderate level of certainty of evidence showed that the mortality risk may be higher in the high-iron group, although the confidence interval also included a potentially beneficial effect. The available data on rates of side-effects showed similar rates in the intervention group compared to the control.

Overall Completeness of Evidence
This review summarized evidence from three RCTs comprising 3205 participants; however, data were not available from all included studies for all outcomes considered in this review. All three studies reported data for mortality and recovery rates, but the data on hemoglobin-related outcomes were available from only two studies and only for a subset of the populations in these studies. Additionally, no data were available regarding the safety outcomes of interest in this review, i.e., clinical deterioration requiring hospitalization. There were also not enough studies to perform all the a priori subgroup analyses, so no conclusions can be drawn at this time for any differential effects of a high iron content in RUTF based on age group (<24 months vs. 24-59 months vs. >59 months), country income level, type of RUTF, type of participants (studies that included children with HIV vs. studies that did not include children with HIV), hospitalization, iron compound, anemia status, or duration of follow-up. Furthermore, each of the three included studies utilized a different dose of iron in the interventional RUTF; therefore, there were not enough data available to perform any statistical analyses to elucidate a dose-response relationship and determine an optimal iron dose in RUTF.

Certainty of Evidence
The certainty of the evidence was graded as low for all the primary outcomes and most of the secondary outcomes ( Table 4). The most common reasons for downgrading the evidence for the primary outcomes were high risk of bias and imprecision. The data were available from only a subset of the study population, and the number of events were small for most of the outcomes. Even though all the studies were conducted in Africa, we did not downgrade for indirectness, as all the included studies had children aged 6-59 months with SAM being managed in community settings. However, we think that the results of the available evidence should be replicated in additional sites in Africa and in Southeast Asia, where the burden of SAM is very high. The pooled data were homogenous for most of the outcomes except the outcomes of recovery from SAM and withdrawal from the studies, in which significant statistical heterogeneity was noted, and the certainty of the evidence was downgraded accordingly.

Potential Bias in the Review Process
We followed the standardized methods of the Cochrane Collaboration to conduct this review. We wrote a protocol for the review that was externally reviewed and publicly available [18]. All titles and abstracts were screened in duplicate, and data extraction was also performed in duplicate for the included studies. We used Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2), a newly developed tool to assess the risk of bias for each outcome from a study rather than a risk of bias assessment applied to all the outcomes from that study (Annex S3 in the Supplementary document). This approach allowed us to give one risk of bias assessment for certain hemoglobin-related outcomes, for which data were available from only a subset of study participants for two of the included studies (high), and a different risk of bias assessment (low) for other outcomes such as mortality and recovery rates, for which data were available from all the study participants from these studies. The authors provided data on some of the hemoglobinrelated outcomes; however, these data were not adjusted for altitude and ethnicity. The data from the other study were adjusted; however, the unadjusted data were available from the primary authors. Thus, we decided to pool the unadjusted data to be consistent and adjusted the certainty of evidence in the GRADE analysis. One of the included studies had two intervention groups that used a high iron content. We used the data from one of the groups, only because the other two included studies had a similar composition of the RUTF-non-dairy, non-peanut-based, and based on soya-maize-sorghum (SMS-based)-which was locally available for the study populations. To the best of our knowledge, there has been no other systematic review published on this topic so we could not compare our findings with other published reviews.

Implications for Practice
The low certainty evidence synthesized in this systematic review showed rates of anemia may be lower and hemoglobin levels may be higher in the intervention group that consumed SMS-based RUTF with a high iron content, compared to the group that consumed peanut-based RUTF with standard WHO-recommended iron content, in children aged 6-59 months with SAM. However, the recovery rates from SAM in the SMS-based high-iron RUTF group were lower, and there was a potentially higher risk of mortality in this group compared to the standard peanut-based RUTF. The lower recovery rates seen in the SMS-based high-iron RUTF group were consistent with those demonstrated in a previous review, which found all non-dairy RUTFs [including soya-maize-sorghum (SMS)based RUTFs]. were associated with lower recovery rates than standard peanut-based RUTF in children with SAM [28]. Thus, the lower recovery rates noted in the included studies in this review could be due to SMS-based macronutrients rather than the iron content of the RUTF. All the included studies used SMS-based RUTF for the high-iron RUTF, so the results cannot be generalized to other forms of RUTF such as those that are peanut-based. Further studies will be required before a solid conclusion can be drawn regarding increasing the iron content in RUTF for the treatment of uncomplicated SAM in children aged 6-59 months.

Implications for Research
Two of the three included studies reported data on blood hemoglobin-related outcomes for a subset of participants. To support the WHO's aim to establish the optimal dose of iron in RUTF for the treatment of children with uncomplicated SAM, there is a need for large randomized controlled trials, preferably utilizing similar RUTF recipes, in which the only difference between formulations is the dose of iron. The studies should be designed to demonstrate a dose-response relationship as well as to assess safety, such as by measuring the number of adverse events and incidence of malaria and diarrhea. The possible increased risk of mortality in the high-iron SMS-based RUFT group also warrants further investigation.

Conclusions
The use of SMS-based RUTF with a high iron content for treating uncomplicated SAM in children aged 6-59 months in community settings may lead to higher blood hemoglobin levels and lower rates of anemia and severe anemia than the use of RUTF with standard WHO-recommended iron content; however, the certainty of the evidence is low for these findings. There is a potential increase in mortality and a decrease in recovery rates in children provided with an SMS-based high-iron RUTF compared to those provided with a peanut-based RUTF with the WHO standard iron dose. Future studies with a large sample size are needed to confirm the beneficial versus harmful effects of a high iron content in RUTF in treating uncomplicated SAM in children aged 6-59 months in community settings.

Institutional Review Board Statement: Not applicable.
Informed Consent Statement: This is a systematic review and did not involve direct contact with human subjects. Data Availability Statement: Further details of data analysis and risk of bias assessments are available on request.